Novavax (NVAX) Operating Expenses (2010 - 2026)

Novavax's Operating Expenses history runs 17 years deep, the most recent figure standing at $154.9 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 2.52% year-over-year to $154.9 million; the TTM figure through Mar 2026 stood at $674.5 million (down 20.04% YoY), while the FY2025 annual figure was $670.7 million, down 27.97% from the prior year.
• Operating Expenses for Q1 2026 stood at $154.9 million, up from $132.9 million in the prior quarter.
• The five-year high for Operating Expenses was $861.8 million in Q3 2022, with the low at $132.9 million in Q4 2025.
• The 5-year median for Operating Expenses is $254.5 million (2024), against an average of $349.0 million.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses surged 77.32% in 2022, then plunged 63.72% in 2023.
• Novavax's Operating Expenses stood at $601.3 million in 2022, then fell by 21.02% to $474.9 million in 2023, then sank by 53.8% to $219.4 million in 2024, then plunged by 39.42% to $132.9 million in 2025, then grew by 16.58% to $154.9 million in 2026.
• Business Quant data shows NVAX's Operating Expenses at $154.9 million in Q1 2026, $132.9 million in Q4 2025, and $248.5 million in Q3 2025.